Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The announcement will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded versions of the medications.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.